(Q36368041)

13 August 2017

1 reference

title

Quo vadis haemapheresis. Current developments in haemapheresis (English)

1 reference

13 August 2017

Helmut Borberg

1

1 reference

13 August 2017

publication date

10 January 2006

1 reference

Transfusion and Apheresis Science

13 August 2017

published in

1 reference

13 August 2017

volume

34

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

51-73

1 reference

Closed Continuous-flow Centrifuge

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Efficacy of the Latham Blood Processor To Perform Plateletpheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

A new continuous-flow cell separation method based on cell density: principle, apparatus, and preliminary application to separation of human buffy coat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Reversibility of granulocyte adhesion using polyamine-grafted nylon-6 as a new column substrate for granulocyte separation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Separation and retention of human blood cells by surface-affinity chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Current topics on cytapheresis technologies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Leukocytapheresis using a leukocyte removal filter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Mononuclear cell collection using various techniques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal photopheresis technical aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal photochemotherapy: evaluation of two techniques and use in connective tissue disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Small-scale extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: a report of 3 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Single-donor platelet concentrates produced along with packed red blood cells with the Haemonetics MCS 3p: preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Platelet gel as an intraoperatively procured platelet-based alternative to fibrin glue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Autologous fibrin glue: production and clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

A novel, automated method of temperature cycling to produce cryoprecipitate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Myasthenogenicity in the main immunogenic region of acetylcholine receptor as modified by conformational design: an approach to antigenic synthetic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Peptide based adsorbers for therapeutic immunoadsorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

In vitro removal of human IgG autoantibodies by affinity filtration using immobilized L-histidine onto PEVA hollow fiber membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Therapeutic selective adsorption of anti-DNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Beta2-microglobulin-selective adsorbent column (Lixelle) for the treatment of dialysis-related amyloidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Blood purification therapies using dextran sulfate cellulose columns Liposorber and Selesorb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Erythrocytapheresis. A method for rapid extracorporeal elimination of erythrocytes. Results in 65 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Advantages of isovolemic large-volume erythrocytapheresis as a rapidly effective and long-lasting treatment modality for red blood cell depletion in patients with polycythemia vera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Therapeutic apheresis in hematological and oncological diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Erythrocytapheresis with Recombinant Human Erythropoietin in Hereditary Hemochromatosis Therapy: A New Alternative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Clinical application of therapeutic erythrocytapheresis (TEA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Granulocyte apheresis in inflammatory bowel disease: possible mechanisms of effect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Characterization of antigen-presenting dendritic cells in the peripheral blood and colonic mucosa of patients with ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Antigen-presenting dendritic cells in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Centrifugal leukocyte apheresis for ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Effective maintenance leukocytapheresis for patients with steroid dependent or resistant ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Granulocyte and monocyte adsorption apheresis in a patient with antiglomerular basement membrane glomerulonephritis and active ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Granulocyte transfusion in the G-CSF era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Granulocyte concentrates: how can we assess their quality?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Granulocyte transfusion as a treatment for enterococcal meningoencephalitis after allogeneic bone marrow transplantation from an unrelated donor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Cytomegalovirus infections in cancer patients receiving granulocyte transfusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Origin, maturation and antigen presenting function of dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Dendritic cells: multi-lineal and multi-functional

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Origin and differentiation of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Comparative analysis of dendritic cells derived from blood monocytes or CD34+ hematopoietic progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Dendritic cells: a journey from laboratory to clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Dendritic cells and tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Generation of melanoma-specific cytotoxic T lymphocytes for allogeneic immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Haemopoietic stem-cell transplantation: recent progress and future promise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Overview of autologous stem cell transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Allogeneic peripheral blood stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Autologous stem cell transplantation for adult acute leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Adult stem cells for tissue repair - a new therapeutic concept?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Muscle regeneration by bone marrow-derived myogenic progenitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Myogenic stem cells from the bone marrow: a therapeutic alternative for muscular dystrophy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Purified hematopoietic stem cells can differentiate into hepatocytes in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Mobilized bone marrow cells repair the infarcted heart, improving function and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Bone marrow cells regenerate infarcted myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Bone marrow stem cells contribute to repair of the ischemically injured renal tubule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Neogenesis of cerebellar Purkinje neurons from gene-marked bone marrow cells in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Bone marrow-derived stem cells can differentiate into retinal cells in injured rat retina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Differentiation of marrow stromal cells into photoreceptors in the rat eye.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Gene therapy: shining hopes dented - but not dashed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Dendritic cells: development, function and potential use for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Active immunization of humans with dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Strategies for tumor elimination by cytotoxic T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Donor Lymphocyte Infusions for Patients who Relapse After Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

A clinical role for peripheral blood lymphocyte infusions and perspectives on collection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Graft-versus-Host Disease, the Graft-versus-Leukemia Effect, and Mixed Chimerism following Nonmyeloablative Stem Cell Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Donor lymphocyte infusion for late relapse followed by kidney transplantation for end-stage renal failure after allogeneic bone marrow transplantation for chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Photopheresis: a Clinically Relevant Immunobiologic Response Modifier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

T-cell responses in photoimmune therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Mechanisms of action of extracorporeal photochemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Transimmunization and the evolution of extracorporeal photochemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Sézary syndrome, cutaneous T-cell lymphoma, and extracorporeal photopheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Follow-up of the T-cell clonality in Sezary patients treated by extracorporeal photopheresis using a new assay: the immunoscope technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Applications of extracorporeal photochemotherapy in "non-oncological" diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal photochemotherapy: a treatment for organ graft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal photochemotherapy: a historical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Reversal of acute renal allograft rejection by extracorporeal photopheresis: a case presentation and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Successful treatment of heart transplant rejection with photopheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Photopheresis treatment in severe Crohn disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Antigen-Specific Tolerance Induced by Autoimmunization with Photoinactivated Syngeneic Effector Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Photopheresis for Rheumatoid Arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Sézary syndrome and seronegative polyarthritis: treatment with extracorporeal photochemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The current state of extracorporeal haemorheotherapy: from haemodilution via cascadefiltration to rheohaemapheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

First experience with a ready-for-use rheohemapheresis system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Changes of hemorheological and biochemical parameters after plasma perfusion using a tryptophan-polyvinyl alcohol adsorber leading to clinical improvement in patients suffering from maculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Contribution of fibrinogen and lipoproteins to plasma viscosity in hypercholesterolemia and hypertriglyceridemia: evaluation by selective depletion of low-density lipoproteins or fibrinogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Fibrinogen adsorption in the diabetic foot syndrome and peripheral arterial occlusive disease: first clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Clinical utility of LDL-apheresis in the treatment of sudden hearing loss: a prospective, randomized study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Improvement of macular function by membrane differential filtration in diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The role of rheology in hemapheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Immunoadsorption in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Acute hemodynamic effects during immunoadsorption in patients with dilated cardiomyopathy positive for beta 1-adrenoceptor autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Advances in the understanding of myocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Removal of anti-A/B antibodies with plasmapheresis in ABO-incompatible kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Impact of Ig-Therasorb immunoapheresis on stability of xenogeneic ex vivo porcine liver perfusion--value of aminotransferases and flow rates for the assessment of metabolic graft viability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Evidence for polyreactive xenoreactive antibodies in the repertoire of human anti-swine antibodies: the 'next' humoral barrier to xenotransplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Durable response to combination therapy including staphylococcal protein A immunoadsorption in life-threatening refractory autoimmune hemolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Plasmapheresis in fulminant acute disseminated encephalomyelitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Immunoadsorption and plasma exchange in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Severe exacerbation of pemphigus vulgaris in pregnancy: successful treatment with plasma exchange

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

High-avidity anti-DNA antibody removal from the serum of systemic lupus erythematosus patients by adsorption using dextran sulfate cellulose columns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Anti-DNA antibody kinetics following selective removal by adsorption using dextran sulphate cellulose columns in patients with systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Modular extracorporeal liver support

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal liver perfusion as hepatic assist in acute liver failure: a review of world experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Bioartificial liver: present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors: a morphologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Convective Flow Through a Hollow Fiber Bioartificial Liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporal liver perfusion as hepatic assist in acute liver failure: a review of world experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Practical aspects of the ligand-binding and enzymatic properties of human serum albumin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Application of MARS artificial liver support as bridging therapy before split liver retransplantation in a 15-month-old child.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Treatment with the molecular adsorbent recirculating system in patients with acute liver failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal albumin dialysis in patients with Amanita phalloides poisoning.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Use of molecular adsorbent recirculating system for treatment of refractory pruritus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Emerging indications for MARS dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The sirens' songs of confirmatory sepsis trials: selection bias and sampling error.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The epidemiology of the systemic inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Outcome of patients with sepsis and septic shock after ICU treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The International Sepsis Forum's controversies in sepsis: how will sepsis be treated in 2051?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Risks and benefits of activated protein C treatment for severe sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The use of activated protein C (drotrecogin alfa (activated)) in the treatment of severe sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

A definite role for treatment with activated protein C in sepsis? Yes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

A definite role for treatment with activated protein C in sepsis? Standard use is premature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

7 January 2021

Antiendotoxin strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal blood purification therapy for sepsis and systemic inflammation: its biological rationale.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Clinical review: extracorporeal blood purification in severe sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Artificial organ treatment for multiple organ failure, acute renal failure, and sepsis: recent new trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Do circulating cytokines really matter in sepsis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The use of extracorporeal techniques to remove humoral factors in sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Successful treatment with polymyxin B immobilized fiber of septic shock complicated by renal stone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Effects of long-term hemofiltration on circulating mediators and superoxide production during continuous endotoxin administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Importance of increased ultrafiltration volume and impact on mortality: sepsis and cytokine story and the role for CVVH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Effect of hemodiafiltration and sepsis on chemotaxis of granulocytes and the release of IL-8 and IL-10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

TNF-alpha elimination with high cut-off haemofilters: a feasible clinical modality for septic patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

HELP apheresis in the treatment of sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Treatment of systemic inflammatory response syndrome by push-pull powdered sorbent pheresis: a Phase 1 clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal removal of proinflammatory cytokines by specific absorption onto microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal adsorption of endotoxin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

A new endotoxin adsorption device in Gram-negative sepsis: use of immobilized albumin with the MATISSE adsorber.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Endotoxin adsorbent based on immobilized human serum albumin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Plasmapheresis combined with continuous venovenous hemofiltration in surgical patients with sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Coupled plasma filtration adsorption: rationale, technical development and early clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Hemodynamic response to coupled plasmafiltration-adsorption in human septic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Plasma exchange as a source of protein C for acute onset protein C pathway failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Plasma exchange as rescue therapy in multiple organ failure including acute renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Genetic architecture of the atherogenic lipoprotein(a)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Metabolism of Lp(a): assembly and excretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein(a) in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein(a) in homozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein(a): still an enigma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

The Effects of Lipid-Regulating Therapy on Haemostatic Parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein Lp(a). A risk factor for myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein(a) is a potential coronary risk factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Concentrations of the atherogenic Lp(a) are elevated in FH

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein(a) in renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

LDL-apheresis significantly reduces urinary apo(a) excretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Is apolipoprotein(a) a susceptibility gene for type I diabetes mellitus and related to long-term survival?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Apoprotein(a) phenotypes and plasma lipoprotein(a) concentration in patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Case-control study of serum lipoprotein(a) and apolipoproteins A-I and B in stroke in the young.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein (a) in patients with aortic aneurysmal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Standardization Project for the Measurement of Lipoprotein(a). Phase 2: selection and properties of a proposed secondary reference material for lipoprotein(a).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients > or =65 years of age (The Italian Longitudinal Study on Aging).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

Surface affinity chromatography of human peripheral blood cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

7 January 2021

New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

7 January 2021

Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: a multicenter open label trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

7 January 2021

Extracorporeal adsorbent-based strategies in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

7 January 2021

Extracorporeal treatment for septic patients: new adsorption technologies and their clinical application

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2005.11.001

7 January 2021

10.1016/J.TRANSCI.2005.11.001

Identifiers

DOI

1 reference

13 August 2017

1 reference